ALT5 Sigma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Peter Tassiopoulos

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	4.9yrs
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Peter Tassiopoulos (55 yo)

less than a year

Mandato

Mr. Peter Tassiopoulos is Chief Executive Officer of ALT5 Sigma Corporation from August 2024. Mr. Tassiopoulos brings over many years of leadership experience across the healthcare, finance and technology...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Tony Isaac	President	9.5yrs	US$817.71k	1.74% € 509.1k
Virland Johnson	Chief Financial Officer	7.3yrs	US$349.35k	0% € 0
Peter Tassiopoulos	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Tony Giordano	Chief Scientific Officer	4.9yrs	Nessun dato	Nessun dato
Douglas Flanagan	Chief Formulation Advisor	4.4yrs	Nessun dato	Nessun dato

4.9yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di 5AR1 è considerato esperto (durata media dell'incarico 4.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Tony Isaac	President	9.5yrs	US$817.71k	1.74% € 509.1k
Richard Butler	Independent Director	9.5yrs	US$30.00k	0.10% € 29.2k
John Cooke	Member of Scientific Advisory Board	4.3yrs	Nessun dato	Nessun dato
Nicholas Goeders	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Christopher Kevil	Chair of Scientific Advisory Board	4.8yrs	Nessun dato	Nessun dato
Edgar Ross	Member of Scientific Advisory Board	4.3yrs	Nessun dato	Nessun dato
Nael Hajjar	Independent Director	6.3yrs	US$14.40k	Nessun dato
John Bitar	Independent Director	4.8yrs	US$18.00k	0.014% € 4.2k
Ron Pitters	Independent Director	no data	Nessun dato	Nessun dato
Joshua Beckman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

4.8yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 5AR1 sono considerati esperti (durata media dell'incarico 4.8 anni).

ALT5 Sigma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

Insufficient new directors

JanOne Inc., Annual General Meeting, Oct 09, 2023

Recent updates

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 62%

Investor sentiment improves as stock rises 95%

New minor risk - Profit margin trend

New major risk - Shareholder dilution

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New major risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

Chief Financial Officer recently sold €181k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

New 90-day high: €13.80

New 90-day high: €6.15

Third quarter 2020 earnings released: US$0.43 loss per share

JanOne Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

New 90-day high - €5.05

Earnings released

New 90-day high - €3.26

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media